Rafiq Hasan
Chief Executive Officer • Complement Therapeutics
Rafiq has pursued a highly successful career in the pharma industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as SVP and Global Head of Ophthalmology at Bayer, Rafiq grew the business of Eylea® from launch to over USD 2.5bn in 5 years, including its launch in 5 indications in 3 years.
Also speaking
Takis Athanasopoulos
Chief Executive Officer, Gene & Cell Ltd., Vice President, Gene Therapy Research & Vector Technology • ViGeneron
16 May 2023
Event Info
Sponsorship Opportunities Waiting List
Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.
31 July 2023
